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Glial cells are the most abundant cell type in the central nervous system (CNS) and play
essential roles in maintaining brain homeostasis, forming myelin, and providing support
and protection for neurons, etc. Over the past decade, significant progress has been
made in the reprogramming field. Given the limited accessibility of human glial cells,
in vitro differentiation of human induced pluripotent stem cells (hiPSCs) into glia may
provide not only a valuable research tool for a better understanding of the functions of
glia in the CNS but also a potential cellular source for clinical therapeutic purposes. In this
review, we will summarize up-to-date novel strategies for the committed differentiation
into the three major glial cell types, i.e., astrocyte, oligodendrocyte, and microglia,
from hiPSCs, focusing on the non-neuronal cell effects on the pathology of some
representative neurological diseases. Furthermore, the application of hiPSC-derived glial
cells in neurological disease modeling will be discussed, so as to gain further insights
into the development of new therapeutic targets for treatment of neurological disorders.
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INTRODUCTION
Glial cells are the most abundant cell type in the CNS with a remarkable role both in structure
maintenance and functioning. Glial cells were initially suggested as so-called “nervenkitt” or
nerve-cement, which was first promulgated as a concept in a lecture delivered by Rudolf Virchow
more than 160 years ago. Virchow defined the term “neuroglia” (synonym of glial cells) which
originated from the Greek word “glía” meaning “glue” in English (Kettenmann and Verkhratsky,
2008). An increasing volume of literature has revealed that glial cells are involved in almost every
aspect of neural activity and play critical roles in CNS functions, development, injury, and diseases
(Zhang, 2001; Barres, 2008; Jäkel and Dimou, 2017).
Glial cells were traditionally divided into three categories: astrocytes, oligodendrocytes (OLs),
and microglia. NG2-glia, also known as polydendrocytes, have been identified as a new class of
glial cells that express the NG2 proteoglycan, and been recognized as oligodendrocyte progenitor
cells (OPCs) (Paukert and Bergles, 2006; Nishiyama, 2007; Oberheim et al., 2012). In addition to
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these major classes of glial cells, some specialized glial cells in
distinct areas of brain have also been identified, such as Müller
glia in retina and Bergmann glia in cerebellum (Kettenmann and
Verkhratsky, 2008).
In this review, we will describe recent advances addressing
the roles of the three major neuroglia with respect to their
participation in brain functions, development, and diseases.
Research of human neuroglia development and function has
been hindered by a constellation of challenges, for instance,
the difficulty in the tracing of endogenous glial cells, including
live or post-mortem tissues. In most circumstances, isolation of
one type of neuroglia from post-mortem tissues is difficult; for
example, the first human astrocytes isolated from post-mortem
tissue (Ennas et al., 1992) were unexpectedly contaminated with
other cells including microglia. A major hurdle is the lack of
purification methods to separate neuroglia (Zhang et al., 2016).
Given the limited accessibility to human brain tissues, rodent glial
cells have frequently served as a substitute to deduce the functions
of human glial cells. However, recent studies demonstrate that
rodent neuroglia are insufficient to model human neuroglia-
related diseases/disorders, due to the large differences in the
distribution of neuroglia types, neuroanatomy, and neurogenesis
between rodents and humans (Oberheim et al., 2009). Moreover,
many current methods applied for isolation may alter the
phenotypes of live glial cells as well (Muffat et al., 2016). In
light of these challenges, developing in vitro human glial cell
models may be of great significance. iPSCs have emerged as a
valuable tool for modeling diseases, studying the development
of human CNS, and exploring treatment modalities for CNS
disorders (Li and Izpisua Belmonte, 2016; Hamazaki et al., 2017;
Shi et al., 2017). Yamanaka and colleagues were the first to
achieve the reprogramming of human fibroblasts into iPSCs
by using defined transcription factors (Takahashi et al., 2007).
The great self-renewal and wide differentiation capacities of
iPSCs make it possible to obtain large numbers of variable
cell types in a cell-type-specific manner. Meanwhile, iPSCs can
be generated from patients’ blood cells, skin fibroblasts, and
other somatic cell sources, providing unlimited and valuable
disease-related cells in a personalized manner. In this regard,
generating glial cells from iPSCs has opened up a new area for
investigating the critical roles of glial cells in CNS development,
function, and disease at a cellular level (Chandrasekaran et al.,
2016; Gonzalez et al., 2017). Glial cells are involved in many
neurological diseases, such as amyotrophic lateral sclerosis
(ALS), spinal cord injury (SCI), Alzheimer’s disease (AD), and
multiple sclerosis (MS). hiPSC-derived glial cells may provide
new and ethically acceptable cell sources for glial cell replacement
therapy.
In this review, we first briefly discuss the current knowledge
of glial cells in brain functions and developments, and then
summarize advances in generating the three major neuroglia
cell types (astrocytes, OLs, and microglia) from hiPSCs, with
emphasis on the non-neuronal cell effects on the pathology of
some representative neurological diseases, so as to gain further
insights into the development of new therapeutic targets for
neurological disorders (Figure 1).
CLASSIFICATION AND ORIGIN OF GLIAL
CELLS
Based on the current knowledge, there are mainly three types
of glial cells: astrocytes, OLs, and microglia, differing in their
origins, molecular markers, physiological functions and subtypes
(summarized in Table 1). Astrocytes, as the most numerous type
of glial cells, comprise a heterogeneous group of cell subtypes that
have a crucial role in brain function and development. Based on
our current understanding, astrocytes differ in gene expression,
morphology, physiology, pathology, and metabolism amongst
cortical regions (Doyle et al., 2008; Zhang and Barres, 2010;
Khakh and Sofroniew, 2015). Astrocytes consist of at least four
distinct subtypes of glial fibrillary acidic protein (GFAP)-positive
cells in human brain, while two subtypes in rodents, indicating a
large species difference among mammals.
According to the literature, the four subtypes of human
astrocytes include: protoplasmic astrocytes found in the gray
matter (layers 2–6 of cortex), interlaminar astrocytes (layer 1
of cortex), polarized astrocytes (layer 5–6 of cortex), fibrous
astrocytes that populate the white matter (Oberheim et al., 2006;
Vasile et al., 2017). Nevertheless, there are only protoplasmic and
fibrous astrocytes identified in rodents (Oberheim et al., 2006;
Vasile et al., 2017). In general, the processes of protoplasmic
astrocytes ensheath synapses as well as blood vessels, while
fibrillary (or fibrous) astrocytes ensheath blood vessels and
contact with nodes of Ranvier (Barres, 2008).
OLs are a type of glial cells which distribute throughout
the CNS, and they are generated from OPCs. OPCs were first
isolated from rat optic nerves and defined as bi-potential OL-
type-2 astrocytes, which are positive for A2B5, and can in vitro
differentiate into either OLs or fibrous astrocytes in different
culture conditions (Raff et al., 1983; Ffrench-Constant and Raff,
1986). OPCs, accounting for 3% of all cells in adult human brain,
can be found in both the gray and white matter, but a larger
percentage in the latter (Dawson, 2003; Crawford et al., 2014).
Microglia, the resident macrophages in the brain and spinal
cord, form the innate immune system via active surveillance
through phagocytosing debris and contributing to inflammation
in response to various toxins, pathogens and injury (Tremblay
et al., 2011; Nayak et al., 2014). As themain resident immune cells
in the CNS, microglia activation serves as the major component
of neuro-inflammation whenever pathogens invade, forming
the frontline defense of the CNS immune system (Glass et al.,
2010). When the resting microglia detect any signal of injury or
tissue damage, microglia shift toward an activated state, termed
polarization, and initiate innate immune responses (Durafourt
et al., 2012; Prinz and Priller, 2014). Microglia presented with
dynamic diverse phenotypes depending on the actions of
modulators and signals detected. Microglia activation ranges
from classically activated pro-inflammatory M1 phenotypes to
alternatively activated anti-inflammatory M2 phenotypes (Tang
and Le, 2016). Classically activated M1 phenotype microglia can
be stimulated with lipopolysaccharide (LPS) in combination with
interferon (IFN)-γ. And alternatively activated M2 phenotype
microglia are normally driven by interleukin (IL)-4/IL-13 and
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FIGURE 1 | Differentiation and application of hiPSC-derived glial cells. Human iPSCs (hiPSCs) reprogrammed from healthy person/patient-derived somatic cells can
give rise to glial cells through different differentiation methods, for instance, by directly differentiating hiPSCs into glial cells, or by first inducing hiPSCs into embryoid
bodies (EBs), neural progenitor cells (NPCs), or hematopoietic stem cells. hiPSC-derived glial cells offer a platform for studying the physiology of glia, disease
mechanisms, and glia/neuron interactions in a culture dish. Accumulating evidence has revealed crucial roles of glial cells in the brain, such as rapid and saltatory
conduction, motor skill learning, energy/trophic support, synapse formation, innate immune system function, etc. Meanwhile, hiPSC-derived glial cells can be
transplanted into animal models (amytrophic lateral sclerosis, spinal cord injury, Alzhemier’s disease, multiple sclerosis, etc.) to evaluate the safety and efficacy for
treatment of these diseases.
IL-10/transforming growth factor (TGF)-β (Hu et al., 2012;
Cunningham, 2013). In human brain, M1 microglia firstly take
action to respond to pathogens and release pro-inflammatory
factors, such as IL-6, IL-1β, IL-12, tumor necrosis factor (TNF)-
α, and chemokine C-C motif ligand 2 (CCL2), which may
result in neurotoxicity. In contrast, M2 microglia act as the
major cells to antagonize inflammatory responses by releasing
anti-inflammatory factors, such as IL-10 and TGF-β, promoting
immunosuppression and neuronal protection (Tang and Le,
2016). However, balance of these two phenotypes could shift at
different stages following injury and in neurodegenerative
diseases, which will be discussed in the following
part.
Gliogenesis are generally considered to occur following
neurogenesis during human brain development. Astrocytes and
OLs originate from the embryonic germ layer, also known as
neuroectoderm, consistent with the origin of neurons (Allen
and Barres, 2009). Furthermore, two sources were reported with
respect to the origin of astrocytes: radial glial cells (RGCs)
within the ventricular zone and intermediate progenitors in the
subventricular zone (Ge et al., 2012). First, RGCs generate new
neurons and intermediate progenitors within ventricular zone,
and then the intermediate progenitors generate neurons or glial
cells. RGCs can switch to gliogenesis to produce astrocytes, after
being activated by factors such as bone morphogenetic protein
(BMP)-4 and IL-6 (Chandrasekaran et al., 2016). As to the
origin of OLs, OPC genesis first takes place in the spinal cord
(Goldman and Kuypers, 2015). OPCs start in the motor neuron
progenitor domain of the ventral region, a process dependent
on sonic hedgehog (SHH). This generation phase requires the
expression of oligodendrocyte transcription factor (Olig) 2, the
basic helix-loop-helix transcription factor, which is regulated
by Nkx6 (Takebayashi et al., 2002). In mouse spinal cord, this
ventrally derived subpopulation makes up ∼80% of all OPCs
(Tripathi et al., 2011). The second wave of OPC production is
derived from dorsal neural tube, relying on fibroblast growth
factor (FGF) but independent of SHH signaling or Nkx6 (Cai
et al., 2005; Fogarty et al., 2005). Finally, the third wave of
OPC origination occur at birth (Rowitch and Kriegstein, 2010).
Within the forebrain, production of OPCs is generally similar
to that in spinal cord. In the beginning, OPCs are generated
from Nkx2.1-expressing precursors of the medial ganglionic
eminence and the anterior entopeduncular area; and then these
cells migrate gradually to the entire telencephalon and the cortex
(Kessaris et al., 2006). The subsequent wave appears in lateral
and/or caudal ganglionic eminences of ventral ventricular zone
of the telencephalon which expresses Gsh2 (Kessaris et al., 2006).
During this phase, the downregulation of Gsh2 (also known as
Gsx2) is essential for OPC generation, since it can directly repress
the expression of platelet-derived growth factor receptor alpha
(PDGFRα), a marker of OPCs (Hart et al., 1989; Chapman et al.,
2013; Goldman and Kuypers, 2015). The final stage of OPC
production arises from cortex around birth which is under the
transcriptional control of Emx1. In comparison with astrocytes
and OLs, the origin and the lineage of microglia have been a
subject of debate after their discovery. In fact, the viewpoint that
microglia are of myeloid origin and derived from hematopoietic
stem cells in the yolk sac is favored by a majority (Hickey
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TABLE 1 | Subtypes, origins, molecular markers, and physiological functions of glial cells.
Subtypes Origins Molecular
markers
Functions References
Astrocytes (including
protoplasmic astrocytes,
interlaminar astrocytes,
polarized astrocytes,
and fibrous astrocytes)
Embryonic germ layer (also
known as neuroectoderm); in
details, two sources were
reported about the origin of
neurons: radial glial cells (RGCs)
within the ventricular zone and
intermediate progenitors in the
subventricular zone.
•Glial fibrillary
acid protein
(GFAP) •S100β
•Glutamate
transporter 1
(GLT1) •Nuclear
factor 1A
•Vimentin
•Aquaporin 4
•GLAST 1
•ALDH1
•Regulation of extracellular
neurotransmitter levels (such as
glutamate-glutamine cycle), water
balance, excitotoxicity;
•Control blood flow;
•Supply energy to neurons;
•Maintenance of the blood-brain
barrier;
•In synapse formation and synapse
elimination that remodels neural
circuits;
•Participate in advanced brain
functions.
Oberheim et al., 2006
Vasile et al., 2017
Allen and Barres, 2009
Ge et al., 2012
Coulter and Eid, 2012
MacVicar and Newman, 2015
Clarke and Barres, 2013
Krencik et al., 2011
Cao et al., 2013
Oligodendrocytes Embryonic germ layer (also
known as neuroectoderm); OPC
generates from two origins, both
of which have three waves: (1)
Spinal cord-ventral region, dorsal
neural tube, the specific zone of
the third wave is unclear yet. (2)
Forebrain-the medial ganglionic
eminence and the anterior
entopeduncular area, ventral
ventricular zone of the
telencephalon, cortex.
•Olig2
•NG2
•A2B5
•PDGFRα
•O4
•MBP
•Myelination;
•Rapid and saltatory conduction;
•Energy/trophic metabolism support;
•Maintenance of axonal structural
integrity and “non-inflammatory”
environment;
•Motor skills learning;
•Rapid response to demyelination
injuries.
Cai et al., 2005
Fogarty et al., 2005
Rowitch and Kriegstein, 2010
Kessaris et al., 2006
Goldman and Kuypers, 2015
Hart et al., 1989
Waxman, 1977
Philips and Rothstein, 2017
Crawford et al., 2014
Kondo and Raff, 2000
Microglia (presented with
dynamic diverse
phenotypes, ranging from
classically pro-inflammatory
M1 phenotypes to
alternatively
anti-inflammatory M2
phenotypes)
Myeloid origin and derived from
hematopoietic stem cells in the
yolk sac.
•IBA1
•CD11b
•CD45
•CD68
•TMEM119
•P2RY12
•Form the frontline defense of the
CNS immune system;
•Participate in synaptic pruning and
synaptic plasticity;
•Promote neuronal survival during
development;
•Through phagocytosis to eliminate
resultant cellular debris in the cleanup
system.
Tang and Le, 2016
Greter and Merad, 2013
Muffat et al., 2016
Glass et al., 2010
Wu et al., 2015
Colonna and Butovsky, 2017
Takahashi et al., 2005
and Kimura, 1988; Simard and Rivest, 2004; Greter and Merad,
2013). As the resident macrophages of CNS, microglia display
unique mesodermal ontogeny differing from other adult tissue
monocyte-derived macrophages (Muffat et al., 2016). Moreover,
more definitive evidence suggests that humanmicroglia originate
from primitive myeloid precursors emanating from the yolk sac
and arise before embryonic day 8 in the developmental period,
as demonstrated by fate-mapping analysis (Ginhoux et al., 2010;
Prinz and Priller, 2014).
THE PHYSIOLOGICAL ROLE OF GLIAL
CELLS
Glial cells are indispensable for brain homeostasis, development,
function, and are involved in a variety of neurological diseases.
Here we will discuss the functions of glial cells under
physiological conditions, including balancing ion concentration,
supplying energy, buffering pH, remodeling synapses and
recycling neurotransmitters, supporting neurons and forming
the innate immune system.
In comparison with rodents, astrocytes in human cortex
exhibit greater heterogeneity and diversity, and display
differences in morphology, physiology, gene expression profile,
and electrophysiological properties (Zhang and Barres, 2010;
Khakh and Sofroniew, 2015). Astrocytes maintain brain
homeostasis by multiple dynamic equilibrium adjustments,
including regulation of extracellular neurotransmitter levels,
water balance, excitotoxicity, and control of blood flow (Coulter
and Eid, 2012). Among the neurotransmitters, 80–90% of
extracellular glutamate is uptaken by astrocytes, transformed to
glutamine by glutamine synthetase, and finally converted back to
glutamate after being uptaken into GABAergic and glutamatergic
neurons, known as glutamate-glutamine cycle (Coulter and Eid,
2012; Parpura and Verkhratsky, 2012). Besides, together with
endothelial cells as well as pericytes, astrocytes form the blood-
brain barrier, with their endfoot processes enveloping brain
blood vessels (MacVicar and Newman, 2015). Additionally,
astrocytes supply energy to neurons through ferrying glucose
and oxygen from blood and converting them to lactate, known as
one of the oldest function of astrocytes (Allen and Barres, 2009).
Astrocytes are also actively involved in the formation of synapses
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via direct contact with neurons and indirectly regulate synapse
formation through cytokine factors (Clarke and Barres, 2013).
Moreover, astrocytes play essential roles in synapse elimination
that remodels neural circuits during CNS development (Chung
et al., 2013). With regard to the electrophysiological functions,
astrocytes are not electrically excitable and therefore do not
generate action potentials. Yet the resting membrane potential
of human astrocytes are sustained at −63.9 to −70mV, while
∼-80mV in rodent astrocytes (Oberheim et al., 2012; Vasile
et al., 2017). Especially, astrocytes are demonstrated to actively
participate in advanced brain functions, including coordinating
motor functions (Saab et al., 2012), modulating depressive-like
behaviors (Cao et al., 2013), regulating memory (Orr et al.,
2015), modulating aging (Yin et al., 2017), as well as controlling
circadian behavioral rhythms and sleep-wake cycles (Ding et al.,
2016; Brancaccio et al., 2017). However, due to their diversity,
future work is required for a full characterization of astrocytes.
In the CNS, OLs play a crucial role in supporting neurons.
OLs form myelin, a multi-lamellar lipid structure with high-
resistance, to wrap neuronal axons, thereby ensuring rapid
and saltatory conduction. Demyelinated fibers could lead to
decreased conduction velocity or conduction failure (Waxman,
1977). Between myelinated segments formed by OLs along an
axon or on different axons are unmyelinated portions named
nodes of Ranvier. In addition to their function in saltatory
conduction, more evidence suggests that OLs can also provide
energy support to neurons by being involved in pyruvate cycling
and ATP synthesis, and NG2-OPCs provide support by being
involved in glutamate signaling and homeostasis in the CNS
(Dawson, 2003; Fünfschilling et al., 2012; Lee et al., 2012; Saab
et al., 2013; Philips and Rothstein, 2017). Myelinating OLs are
also critical for the structural integrity of axons and maintain
a “non-inflammatory” environment (Hirrlinger et al., 2002;
Kassmann et al., 2007). Myelination persists in human brain
from birth to adulthood. By testing maximal finger tapping speed
which depends on the myelination process and the integrity of
myelin, it was shown that the maximum motor speed appears
in middle-aged men and declines in older ones (Bartzokis et al.,
2010). OPCs are the major cell source of myelination. Within
the adults CNS, OPCs could be activated from a quiescent state
by demyelination injuries and take rapid responses (Crawford
et al., 2014). OPCs would proliferate, migrate, and differentiate
into mature myelinating OLs and ultimately remyelination is
achieved. Notably, remyelination efficiency declines with age,
as characterized by the decreasing rate of cell division, the
delay in OPC recruitment and differentiation, and the decline
of myelin content and integrity in brain (Sim et al., 2002;
Bartzokis et al., 2010; Richardson et al., 2011; Young et al., 2013).
Another notable phenomenon is that the myelin internodes
become shorter but the number of the nodes increases with age
(Young et al., 2013). The cause of this phenomenon is unclear,
whereas it was proposed that the change may be related to the
speed of conduction. Furthermore, myelination is associated with
motor skill learning. For example, OPC proliferation and OL
production have been shown in the corpus callosum of mice,
which is triggered by a novel experience running on complex
wheels with irregularly spaced rungs (McKenzie et al., 2014; Xiao
et al., 2016). The proliferation of OPCs seems to be influenced by
the electrical activity of axons in close proximity (Barres and Raff,
1993). OPCs could form direct synapses with neurons in both
gray and whitematters and they have the potential to differentiate
into astrocytes or neurons under specific conditions (Raff et al.,
1983; Ffrench-Constant and Raff, 1986; Kondo and Raff, 2000).
OPCs can also transform into cancer cells caused by expression
or deletion of some specific genes (Bergles and Richardson, 2016).
Microglia facilitate the wiring of neural networks via
migration into the CNS as the first glial cells (Colonna
and Butovsky, 2017). During prenatal development, microglia
as guidepost cells play significant roles at the crossroads
of axonal fiber pathways and neural migratory routes in
guiding neurons and axons to form neural circuits (Squarzoni
et al., 2015). Furthermore, emerging evidence indicates that
microglia take active part in the developmental synaptic pruning
and synaptic plasticity (Wu et al., 2015). Deficiency of a
transmembrane polypeptide DAP12, restrictedly expressed in
microglia, impaired synaptic function through reducing the
expression of brain-derived neurotrophic factor-tyrosine kinase
receptor B (Roumier et al., 2004). Microglial behavior could
increase phagocytosis of synaptic elements and interact with
subsets of structurally dynamic and transient synapses (Wake
et al., 2009; Tremblay et al., 2010). Under two-photon in
vivo imaging and electron microscopy, processes of microglia
actively contact with dendritic spines, highlighting the role of
microglia in synaptic activity and plasticity (Tremblay et al.,
2010). Some trophic factors and synaptogenic signals derived
from microglia are significant for synaptic pruning. Moreover,
microglia can release some trophic factors to promote the
survival of surrounding neurons. For example, insulin-like
growth factor-1 derived from microglia supports the survival
of layer 5 cortical neurons (Ueno et al., 2013). Besides,
microglia secrete some growth factors, include FGF, and
other neurotrophic factors like glial cell-derived neurotrophic
factor, brain-derived neurotrophic factor and nerve growth
factors, which are essential facilitators of neuronal growth and
health (Colonna and Butovsky, 2017). Nevertheless, microglia
not only promote neuronal survival during development,
but are also in part responsible for inducing neuronal
death. In fact, approximately half of the immature or faulty
neurons caused by improper migration or differentiation
assume programmed cell death and require elimination (Nayak
et al., 2014). As expected, microglia play an active role
in the cleanup system through phagocytosis to eliminate
resultant cellular debris (Takahashi et al., 2005; Hristova
et al., 2010); after status epilepticus in which situation the
number of newborn cells increases rapidly, for example,
microglia are rapidly activated and eliminate some newborn
cells in the subgranular zone by phagocytosis (Luo et al.,
2016). Taken together, microglia perform indispensable roles
and contribute to the microenvironment homeostasis and
the dynamic change of neural circuits via secreting various
neurotoxic or neuroprotective factors involved in the process of
induced neuronal death/clean up or neurogenesis.
Appropriate interaction between neurons and glia is crucial
for the maintenance of the nervous system homeostasis. A
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commonsense notion is that glial cells constitute about 90% of all
cells in human brain and glia/neuron ratio increases with brain
size across different species (Ullian et al., 2001; Nishiyama et al.,
2005). Yet this notion has been challenged by Herculano-Houzel
et al. who proposed that the glia/neuron ratio does not increase
with brain size but with decreasing neuronal density, and human
brain consists of roughly 50% neuronal and 50% non-neuronal
cells (Herculano-Houzel, 2014).
In most studies, mouse- and rat-derived glial cells have been
employed as the primary subject to study the biology and
pathology of human glia. In spite of some similarities, it is also
noteworthy to stress the fundamental differences in human vs.
rodent glial cells, which may have accounted for the numerous
failures of drug discovery in translating rodent studies to humans.
(i) Different subtypes of astrocytes exist between human and
rodent astrocytes. Only protoplasmic and fibrous astrocytes have
been identified in rodents, whereas two additional subtypes,
interlaminar and polarized astrocytes, have been identified in
human (Oberheim et al., 2009). (ii) Human astrocytes cover
larger territories than do rodent astrocytes. Oberheim et al. first
found that human astrocytes are significantly larger in size than
rodent astrocytes in vivo. Then to find out whether intrinsic
qualities or non-cell-autonomous pathways contribute to the
larger size, Zhang et al. purified astrocytes by immunopanning
and cultured them in vitro, and showed that the length of human
astrocyte processes are almost twice of that of rodent cells in vitro
(Zhang et al., 2016). (iii) Human astrocytes have almost twice
the number of branches as many as rodent astrocytes, which are
8.5 ± 1.1 and 4.5 ± 0.5, respectively (Zhang et al., 2016). (iv)
Human astrocytes are 2.6-fold larger in diameter than rodent
astrocytes. (v) The ratio of glial cells to neurons is much larger
in human vs. in rodent, which are ∼1.65:1 in human and ∼0.3:1
in rodents, respectively (Nedergaard et al., 2003; Sherwood et al.,
2006). (vi) As rodent astrocytes do, human astrocytes respond
to glutamate and ATP through calcium waves, but with a faster
speed for propagating calcium signals (Zhang et al., 2016).
Albeit the above, it remains an intriguing question whether such
a difference leads to distinction of cognitive abilities between
human and rodent animals. Also, given the high frequency of
drug discovery failures in translation of rodent data to humans,
the difference of glia between species should be taken into
consideration, particularly in translational studies. To overcome
these obstacles, generating glial cells from hiPSCs may provide a
solution.
CURRENT APPOACHES FOR GLIAL
DIFFERENTIATION FROM HIPSCS
Astrocytes
Research of glial cells related to neurological diseases has been
hindered by some challenges as listed below: limited accessibility
of neural tissues, difficulties in culturing glia in vitro (current
isolation method may change the phenotypes), and the large
difference between rodent models and human diseases due to the
distinctions in glial cell morphology, distribution, and function
between species (Oberheim et al., 2006, 2009). hiPSCs are at the
forefront of research in neurological diseases and are recognized
as a source for generating autologous donor cells for disease
modeling, drug discovery, and replacement therapy (Kikuchi
et al., 2017). Improved differentiation of glial cells from hiPSCs
can generate a large number of glial cells in an iterative and
controlled manner.
In the case of astrocytes, many studies have focused on the
differentiation of astrocytes from hiPSCs. Figure 2 summarizes
the current approaches for astrocyte differentiation from hiPSCs.
A chemically defined differentiation system was first reported
for efficient production of astroglial progenitors and immature
astrocytes from hiPSCs in large quantities (estimated 2.8 × 1012
immature astrocytes) through a 6-month long term expansion
process in the presence of FGF2 and epidermal growth factor
(EGF) (Krencik et al., 2011). In detail, astrocyte differentiation
includes three major stages; hiPSCs are first differentiated into
neuroepithelial cells (days 0–21), then to astroglial progenitors
with addition of EGF and FGF2 in the medium (days 21–
90), and finally immature astrocytes are generated (days >90).
Astroglial progenitors and immature astrocytes express NFIA-
S100β at 4–8 weeks, and express more mature markers CD44-
GFAP by 8–12 weeks of differentiation. Besides, these hiPSC-
derived astrocytes display functional hallmarks that include
possessing glutamate receptors and transporters, propagating
calcium waves, promoting synaptogenesis, and taking part in
the formation of the blood-brain barrier (Krencik et al., 2011).
Moreover, these differentiated astrocytes are not contaminated
with other cell types, such as microglia, in comparison with
primary astrocyte cultures (Krencik and Zhang, 2011). In the
subsequent years, the period of astrocyte differentiation from
iPSCs was further shortened to 35–80 days by manually picking
rosettes on the initial stage of neural precursor generation
(Emdad et al., 2012; Juopperi et al., 2012; Lafaille et al., 2012;
Shaltouki et al., 2013). Since iPSCs have been confirmed to be
able to differentiate to astrocytes, the next question is how to
optimize the differentiation process. Compared with traditional
two-dimensional (2-D) adherent culture, Zhou et al. employed a
3-D floating neurosphere system to increase the yield of neural
progenitors positive for PAX6 and NESTIN, compared with 2-
D adherent monolayer culture, which subsequently improved
the efficiency of astrocyte generation from iPSCs, as monitored
by GFAP and aquaporin 4 expression (Zhou et al., 2016). On
the other hand, reliable 3-D-based culture methods, have proved
to be able to accelerate astrocyte differentiation, and shorten
the time frame, compared with the traditional 2-D method.
Furthermore, human embryonic stem cells (hESCs) have been
demonstrated to differentiate to neurons and glia in a chemically
defined culture (Li et al., 2005; Watanabe et al., 2007; Yang et al.,
2008). Hu et al. compared the neural-differentiation capacity
between hiPSCs and hESCs and found hiPSCs differentiate to
neuroepithelia and functional neurons and glia over similar
temporal patterns as hESCs do but with increased variability and
reduced efficiency (Hu et al., 2010). The results indicate that
not only techniques are needed to improve the differentiation
potency of iPSCs, but better criteria are also needed to select
more uniform iPSCs. Later, Emdad et al. utilized two hESC and
two hiPSC lines and specified them to neuro-epithelial lineages
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FIGURE 2 | Current approaches for deriving astrocytes from hiPSCs. Krencik et al. produced astroglial progenitors and immature astrocytes differentiated from
hiPSCs through a 6-month process in the presence of FGF2 and EGF. Zhou et al. employed a 3-D floating neurosphere system to increase the efficiency and to
shorten the time frame of astrocytes differentiation. Hu et al. and Emdad et al. compared the time course, variability and efficiency using hiPSCs vs. hESCs for
differentiation into astrocytes. Roybon et al. reported that FGF1 or FGF2 can promote maturation to a quiescence state without triggering inflammation; yet TNF-α and
IL-1β have opposite effects and induce a reactive inflammatory state of astrocytes.
and then to astrocytes (Emdad et al., 2012). They found that
hiPSCs are differentiated to astrocytes in a similar time course
and with a comparable efficiency vs. hESCs (Emdad et al.,
2012).
Actually, a complex interaction between intrinsic gene
expression and extrinsic environmental factors regulates
neurogenesis and gliogenesis during embryonic development.
It is necessary to take intrinsic and extrinsic factors into
consideration, such as reprogramming transgenes in iPSCs,
culture conditions, and differentiation protocols, etc.
Nevertheless, most existing protocols yield only immature
astrocytes and the phenotypes of astrocytes are extremely
dynamic. For instance, ischemia and pro-inflammatory factors
can induce reactive astrocytes, which can be further categorized
into A1 (harmful) and A2 (helpful) astrocytes (Liddelow and
Barres, 2017; Liddelow et al., 2017). From the application
standpoint, quiescent mature astrocytes are essential for
modeling normal development and functions whereas reactive
astrocytes are conducive to studies involving the modeling
of human pathological processes in vitro. Indeed, GFAP+
astrocytes obtained through standard protocols are of immature
reactive phenotypes, marked by high GFAP and low glutamate
transporter 1 (GLT1) expression compared with quiescent state
which shows high GLT1 and low GFAP expression (Zamanian
et al., 2012). Therefore, it is important to develop a robust
method to generate mature, quiescent astrocytes, so as to
facilitate a better understanding of astrocyte function in health
and disease. Roybon et al. reported that FGF1 or FGF2 can
promote maturation to a quiescence state without triggering
inflammation; yet TNF-α and IL-1β have opposite effect and
induce a reactive inflammatory state of astrocytes (Roybon et al.,
2013).
OLs
OLs have a powerful myelinating capacity and have become
the optimal cell source for modeling and treating demyelinating
diseases. Figure 3 summarizes the current approaches for
differentiation of OLs from hiPSCs. Hu et al. used SHH, both a
ventralizing morphogen and a mitogen (Goldman and Kuypers,
2015), as a key factor to induce OLs from hESCs (Hu B. Y. et al.,
2009). After 16 weeks of differentiation, O4+ OLs can be obtained
and reached around 40% of all cells (Hu B. Y. et al., 2009). After
that, more protocols were reported (Hatch et al., 2009; Hu Z.
et al., 2009; Stacpoole et al., 2013; Wang et al., 2013; Major et al.,
2017).
Compared with hESCs, hiPSCs possess certain advantages and
raise fewer ethical and transplantation-associated immunological
problems. In 2012, Song et al. reported that skin cells-derived
iPSCs from MS patient could be successfully differentiated
into OLs, astrocytes and neurons (Song et al., 2012). This
study provided a new approach to MS research. To assess the
myelinating capacity, Wang et al. developed a 6-stage strategy
by adding different small molecules at different stages and
transplanted iPSCs-derived OPCs into shiverer mice (a mouse
model deficient in myelination) (Wang et al., 2013). Three
healthy people-derived iPSC lines were differentiated into OPCs,
which took 110–150 days, with a high efficiency of around
80% (Wang et al., 2013). These OPCs can produce myelin
basic protein (MBP) when co-cultured with human axons; after
transplantation into newborn shiverer mice, the OPCs robustly
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FIGURE 3 | Current approaches for deriving OLs from hiPSCs. Oligodendrocytes can be induced from both hESCs and hiPSCs. (A) Wang, Douvaras and Li et al.
induced hiPSCs, including MS patient-iPSCs, intoOPCs, respectively. Besides, they accelerated the process by adding different small molecules or infecting virus.
(B) In order to better understand the role of OPCs in related diseases, several groups have differentiated patient-iPSCs into OPCs, such as Pelizaeus-Merzbacher
disease (PMD), X-linked adrenoleukodystrophy (X-ALD). Additionally, generation of a stable and expandable intermediate, oligodendrogenic NPCs, could provide a
convenience advantage for potential clinical applications. (C) In 2009, Hu et al. used SHH as a key factor to induce OLs from hESCs. And Stacpoole et al. shortened
the differentiation period to 120 days by inducing OPCs in a low oxygen tension environment. Compared with the traditional 2-D culture system, Rodrigues et al.
successfully generated hESCs and hiPSCs into OPCs in 3-D systems, which could get higher yields of OPCs and may also provide a platform to study the cell-cell
interactions in vitro.
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myelinate the brain and significantly improve the survival rate
of the mice (Wang et al., 2013). Importantly, there is no
sign of tumor formation 9 months post-transplantation (Wang
et al., 2013). Although this protocol could achieve a higher
OPC production than previous methods, it is still a lengthy
process. A more efficient protocol that takes less time would
be favorable. To meet this need, Stacpoole et al. showed that
OPCs could be obtained in a shorter period of time with a high
yield by inducing them in a low oxygen tension environment
(Stacpoole et al., 2013). After 120 days, 87% of total cells are
Olig2+/NG2+ double positive, and a few cells express O4; and
following another week, the proportion of O4+ cells increase to
46% (Stacpoole et al., 2013). Douvaras et al. applied dual SMAD
inhibition for neural induction under an adherent condition
and determined the optimal concentration of retinoic acid (RA)
and successfully differentiated OLs from primary progressive
multiple sclerosis patients (PPMS)-derived iPSCs (Douvaras
et al., 2014). With this method, 28–80% O4+ OPCs can be
generated within 75 days and O4-sorted cells have the capacity
of myelination in shiverer mice (Douvaras et al., 2014). They
suggested that PPMS-derived OPCs have equal functions to
those derived from healthy subjects (Douvaras et al., 2014). In
their follow-up studies, the differentiation time to obtain O4+
cells is further shortened from 75 to 55 days (Douvaras and
Fossati, 2015). Later on, Li et al. applied a concept of “forward
patterning” to accelerate the OPC differentiation from iPSCs
by a forced expression of Sox10 and/or Olig2 in iPSCs. In this
way, they can obtain PDGFRα+ OPCs in 14 days and O4+
OPCs in 56 days (Li et al., 2016). Additionally, to accelerate the
differentiation to OPCs and OL2, addition of small molecules,
such as clemastine and benzatropine (Mei et al., 2014), may be
considered.
In addition to MS, Pelizaeus-Merzbacher disease (PMD)
and X-linked adrenoleukodystrophy (X-ALD) are two diseases
in which OLs are closely involved. Several groups have
independently generated OLs from PMD and X-ALD patients-
specific iPSCs (Jang et al., 2011; Numasawa-Kuroiwa et al.,
2014; Nevin et al., 2017). Numasawa-Kuroiwa et al. achieved
OPC differentiation by first inducing iPSCs into embryoid
bodies (EBs) and then neurospheres using small molecules that
inhibit dual SMAD and GSK3 pathways. After 10–12 weeks of
differentiation, MBP+ mature OLs appear (Numasawa-Kuroiwa
et al., 2014). Later on, Nevin et al. differentiated OPCs from 12
PMD iPSC lines and 7 control iPSC lines, using the protocol
developed byDouvaras et al. (Douvaras et al., 2014; Douvaras and
Fossati, 2015; Nevin et al., 2017). PMD patients-specific iPSCs-
derived OPCs exhibit defects in process extension and branching
in vitro and in vivo (Numasawa-Kuroiwa et al., 2014; Nevin
et al., 2017). Jang et al. induced X-ALD patients-specific iPSCs
into spherical neural masses (SNMs), then differentiated SNMs
to OPCs by treatment with several small molecules (Jang et al.,
2011). This is the first report of X-ALD iPSCs-derived OPCs, and
the authors found that the level of very long chain fatty acid in X-
ALD OPCs is significantly higher than in normal controls (Jang
et al., 2011).
In addition to these studies, other methods have also been
reported. Gorris et al. differentiated iPSCs to an intermediate
neural progenitor cells (NPCs) state that are predisposed to
oligodendrocyte fate specification (oligodendrogenic NPCs). The
oligodendrogenic NPCs can be stocked and frozen for future
use—a convenience advantage for potential clinical application
(Gorris et al., 2015; Khazaei et al., 2017).
A 2-D cell culture system was used in the above studies,
which shows limitations in mimicking the cell-cell interactions
in human brain. To address this issue, researchers have developed
3-D culture systems for OPC differentiation (Egawa et al., 2017;
Rodrigues et al., 2017). Egawa et al. developed a 3-D system using
gels composed of a mixture of collagen and hyaluronan, in which
rat primary OPCs can proliferate and differentiate into mature
OLs (Egawa et al., 2017). In the study of Rodrigues et al., OPCs
are generated in a 3-D system based on a hydrogel material. Three
hESC lines and one iPSC line are induced to OPCs by using the
dual-SMAD inhibitors (SB431542 and LDN193189), SAG, and
RA; O4+ cells appear on day 55, and then the MBP+ OLs are
produced on day 95 with a higher yield than with a 2-D culture
system. To evaluate the functions of OPCs, the authors injected
the 50-day-old cells into NOD/SCID (non-obese diabetic-severe
combined immunodeficient) mouse brains and found these cells
can proliferate and migrate in vivo after 6 months. Moreover, the
OPCs generated in the 3-D culture also have spiking behaviors
(Rodrigues et al., 2017).
The current differentiation methods all give rise to a
heterogeneous population consisting of not only OLs, but also
other cell types, such as astrocytes and neurons. O4-sorted OPCs
have to be engrafted immediately, or cultured together with
other cells for expansion or for functional analysis; sorted OPCs
cannot survive passaging as a pure population. Future studies are
required to determine a culture condition in which sorted OPCs
can be further expanded.
Microglia
Microglia have aroused more attention in recent years as
significant modulators of neurogenesis, development, function,
and pathogenesis of the CNS. However, similar challenges exist in
microglial research, which include limited accessibility of human
neural tissues, phenotype of microglia being unpredictably
changed by current isolation methods, difficulties in culturing
microglia in vitro, and the fact that murine glial cells cannot
simulate all the features of primary human glial cells. One
solution to overcome these hurdles is to derive microglia from
hiPSCs using a chemically defined method. Although many
studies have focused on the differentiation of hiPSCs to astrocytes
and OLs, only very limited studies have reported successful
generation of microglia from hiPSCs. Figure 4 summarizes
the current approaches for microglia differentiation from
hiPSCs. One of the reasons lies in the fact that microglia are
derived from yolk sac myeloid precursors, which cannot be
produced from neural progenitors as astrocytes and OLs can
be. Nevertheless, Muffat et al. first established a protocol in
which neuroglial differentiation (NGD) medium with addition
of colony-stimulating factor 1 (CSF1) and IL-34 was used for
generating hiPSC-derived microglia-like cells, which resemble
primary fetal and human adult microglia (Muffat et al., 2016).
In detail, colonies were triturated mildly to form a suspension
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FIGURE 4 | Current approaches for deriving microglia from hiPSCs. Muffat et al. demonstrated that hiPSCs can be differentiated to microglia with neuroglial
differentiation (NGD) media in the presence of CSF1 and IL-34, and the obtained cells possess the functions of phagocytes positive for microglial markers such as
TMEM119 and P2RY12. Pandya et al. reported another method that applies co-culture with astrocytes for differentiation of hiPSCs to microglia-like cells via a
hematopoietic progenitor-like intermediate stage. And Abud et al. established a fully defined and serum-free method to derive microglia-like cells from hiPSCs with
robust scalability and high purity, via differentiating first toward hematopoiesis stem cells and then to microglia.
of EBs and transferred to NGD medium (10 ng/ml CSF1 and
10 ng/ml IL-34) (Muffat et al., 2016). One of the two main types
of EBs formed presented with large, expanding cystic bodies,
and were called yolk sac EBs (YS-EBs). Then YS-EBs were
triturated every 5 days to shear off loose cells, and EBs that were
attached on Primaria plates were selected (Muffat et al., 2016).
Muffat et al. also demonstrated that hiPSC-derived microglia are
capable of migration and proliferation, possessing the functions
of phagocytes positive for microglial markers such as IBA1,
CD11B, CD45, TMEM119, and P2RY12 (Muffat et al., 2016).
Besides, 20 different ES and iPSC lines have been differentiated
to microglia successfully to ensure the reproducibility of the
protocol, allowing for robust and efficient generation of microglia
from iPSCs of different genetic backgrounds (Muffat et al., 2016).
Later, Pandya et al. reported another method for differentiation
of hiPSC into microglia-like cells via a hematopoietic progenitor-
like intermediate stage, instead of through neural intermediate
stage used for astrocyte and OPC differentiation, which is more
consistent with the embryonic development in vivo (Pandya
et al., 2017). In the protocol of Pandya et al., hiPSCs were
cultured feerder-free in media A (STEMdiff APEL medium with
hVEGF, hBMP4, hSCF and hActivin A) for the first 4 days
(Pandya et al., 2017). Then on days 4, 7, 10, media A was
changed tomedia B (STEMdiff APELmediumwith hSCF, hFlt3L,
hIL-3, hIL-6, hG-CSF, and hBMP4) (Pandya et al., 2017). On
day 15, cells were harvested and plated onto human astrocytes
for 1–2 weeks for differentiation into microglia (Pandya et al.,
2017). The microglia-like cells show functional properties,
including producing reactive oxygen species, phagocytosing
cellular debris, secreting pro-inflammatory factors (Pandya et al.,
2017). Microglia derived from murine iPSCs are able to increase
the survival of mice with intracranial malignant gliomas (Pandya
et al., 2017). In this study, the murine microglia were obtained
through a similar protocol as used to generate hiPSC-derived
microglia-like cells (Pandya et al., 2017). Significantly, in the
published protocol, Pandya et al. utilized astrocytes differentiated
from the same starting hiPSCs as feeder cells to facilitate
generation of human microglia; avoiding the use of murine cells
and the subsequent introduction of xenogeneic cells/proteins
are advantageous for possible future clinical applications using
hiPSC-derived microglia (Pandya et al., 2017). Furthermore, the
Pandya method shortens the differentiation period from 8 to
4 weeks by using a co-culture system with hiPSC-astrocytes;
the culture medium is also improved to a factor-defined one,
instead of using a serum-based medium (Pandya et al., 2017).
More recently, a highly efficient, fully defined and serum-
free method was described for differentiating microglia-like
cells from hiPSCs with robust scalability and high purity, via
differentiating toward hematopoiesis stem cells and then to
microglia (Abud et al., 2017). Whole-transcriptome analysis and
functional assessment revealed that microglia-like cells derived
from hiPSCs are similar to those derived from human fetal
and adult tissues (Abud et al., 2017). In summary, these fully
defined protocols can produce a large number of microglia-
like cells, which offers a renewable source of cells to investigate
the roles of microglia in normal CNS development, functions,
and homeostasis, as well as the roles in various neurological
diseases. However, there still exists a pressing need to further
promote the yield, purity and scalability of microglia derived
from hiPSCs.
Based on the critical roles of glial cells in CNS physiology,
it is not surprising that glial cell dysfunction has been involved
in many neurological diseases. In the next part, we will discuss
recent advancements on the non-neuronal cell-autonomous
effects of glia in some representative neurological diseases
(summarized in Table 2), with an eye toward using iPSC-derived
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glial cells to create once inaccessible cell types, providing new
tools to model complex neurological diseases, and developing
new targets for autologous cell transplantation.
POTENTIAL APPLICATION OF
HIPSC-DERIVED GLIAL CELLS IN
NEUROLOGICAL DISEASES AND CELL
REPLACEMENT THERAPY
Amyotrophic Lateral Sclerosis
ALS is an adult-onset disorder that is characterized by rapid
selective upper or lower motor neuron degeneration, resulting
in hyperreflexia, spasticity (upper motor neurons), muscle
weakness, and paralysis (lower motor neurons) and ultimately
fatal respiratory failure (Rowland and Shneider, 2001; Kiernan
et al., 2011). About 5–10% of classical ALS cases are familial,
and the remaining sporadic (Brown, 1997). With regard to
the mechanism of ALS, mutations in the Cu/Zn superoxide
dismutase 1 (SOD1) gene have been identified as the main
cause of ∼20% familial ALS (Brown, 1997; Bruijn et al., 2004).
In spite of much effort that has been made in the past two
decades, there is still no effective therapy to slow down the
disease progression. Besides, modeling ALS with transgenic
rodent animals is costly and time-consuming since ALS is a
slowly developing neurodegenerative disorder, requiring months
of modeling using transgenic rodent animals. Therefore, utilizing
hiPSC-based in vitro models of ALS has attracted interest in the
research community. Some studies have emphasized the role of
neuroglia in the pathogenesis of ALS. Astrocytes derived from
both sporadic ALS patients and familial ALS patients have been
demonstrated to be toxic to non-ALS derived motor neurons,
suggesting that sporadic ALS and familial ALS may share a
similar mechanism through astrocytes-mediated cellular toxicity
(Haidet-Phillips et al., 2011). And knockdown of mutant SOD1
in astrocytes results in a significant rescue of astrocyte-derived
toxicity toward motor neurons, indicating that mutant SOD1
in astrocytes can be recognized as a potential therapeutic target
for ALS (Haidet-Phillips et al., 2011). Furthermore, Bi et al. has
demonstrated that lipocalin as a potent mediator of astrocytic
toxicity is secreted by reactive astrocytes and is highly selectively
toxic to neurons, especially to the unhealthy neurons which
express ALS related genes, such as mutant TAR DNA-binding
protein 43 and RNA-binding protein fused in sarcoma (Bi et al.,
2013). To explore whether astrocyte-specific influences on motor
neurons in ALS can translate in vivo, Papadeas et al. transplanted
glial-restricted precursors harboring the human G93A mutation
(SOD1G93A) into the spinal cord of wild type rats, and the donor
cells differentiated into astrocytes in rats eventually (Papadeas
et al., 2011). The results showed that SOD1G93A astrocytes
can cause motor neuron pathology and death, respiratory
and forelimb motor dysfunction, as well as a reduced GLT1
transporter expression in rats (Papadeas et al., 2011). Moreover,
targeted enrichment of normal astrocytes into mutant SOD1
rats to facilitate restoration of motor neuron function has been
investigated by Kondo et al. (Kondo et al., 2014). Transplantation
of hiPSC-derived glia-rich progenitors, which then gave rise to
astrocytes, into the lumbar spinal cord of ALS mice improved the
motor function and prolonged the lifespan of mice via activation
of AKT signals (Kondo et al., 2014), exemplifying the rationale of
cell therapy for ALS using hiPSC-derived glial cells. Consistent
findings were also observed when glial-restricted precursors
were transplanted into the cervical spinal cord of 90-day old
SOD1G93A rats (Lepore et al., 2008). Glial-restricted precursors
survived, attenuated motor neuron death, and extended the
lifespan of animals (Lepore et al., 2008). These data support that
astrocyte dysfunction may serve as a propagator of motor neuron
degeneration in ALS, and astrocytes may play critical roles in
SOD1 mutation-mediated ALS, although it remains unknown
whether astrocyte dysfunction is a driver or consequence of
ALS. Based on the evidence that astrocytes-derived toxicity plays
an active role in motor neuron death in ALS, astrocytes may
represent a potential therapeutic target in ALS; replacement
of dysfunctional astrocytes or enrichment of normal astrocytes
with functioning astrocytes, may serve as one potential approach
in ALS therapy. With respect to clinical trials, an open label
phase I/IIa study (NCT03482050), aimed to evaluate the safety,
tolerability and therapeutic effects of astrocyte transplant derived
from hESCs to treat ALS patients, is recruiting participants
at present. In this trial, astrocytes derived from hESCs will
be administered through intrathecal (spinal) injection with an
escalating low, medium, and high dose or two consecutive
administrations of medium dose with an interval. The study
will test the hypothesis that transplantation of astrocytes may
compensate for the patients’ own dysfunctional astrocytes via
restoring the normal physiological functions that include, for
example, reducing oxidative stress and other toxic compounds
as well as regulating extracellular neurotransmitter levels. This
study will be the first to apply stem cells-derived astrocyte graft
into patients with ALS, accelerating the translation of stem cell
biology to clinical applications to treat neurological diseases.
Besides, another clinical trial (NCT02943850), aimed to examine
the safety of transplanting GDNF-producing NPCs into the
spinal cord of ALS patients, is recruiting participants now. This
trial is a single-center, Phase 1/2a study using two escalating
doses of human NPCs expressing GDNF, which will be injected
unilaterally into the lumbar region of ALS patients withmoderate
leg involvement. This is the first trial to use genetically modified
progenitors to treat ALS.
Microglia have also been identified as a critical player in ALS
progression. Microglia are activated in areas where motor neuron
loss takes place, contributing to the death of motor neurons
(Philips and Robberecht, 2011). Nuclear factor-kappa B (NF-κB)
pathway, a mediator of inflammation, was suggested as a possible
mechanism of microglia-mediated motor neuron death (Frakes
et al., 2014). Minocycline, a second-generation tetracycline, is
capable of delaying ALS progression and extending the life span
of ALS mice through inhibiting microglial activation, suggesting
that certain antibiotics may serve as a potential drug for ALS
via inhibiting microglial activation (Yrjänheikki et al., 1999;
Zhu et al., 2002). Microglia isolated from mutant SOD1G93A
transgenic mice and activated by LPS treatment are more
neurotoxic to motor neurons compared with wild-type microglia
(Xiao et al., 2007). Furthermore, Boillée et al. found that removal
of mutant SOD1 gene frommicroglia had little effect on the early
disease onset whereas slowed down disease progression during
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TABLE 2 | Potential application of hiPSC-derived glial cells in neurodegenerative diseases and cell replacement therapy.
Diseases
involving glia
Cell types Representative roles in disease
pathology
Potential applications Challenges References
Amyotrophic
lateral sclerosis
(ALS)
Astrocytes Astrocytes from ALS patients are
toxic to non-ALS derived motor
neurons; selective knockdown of
mSOD1 in astrocytes results in a
significant rescue of astrocyte-derived
toxicity; SOD1G93A astrocytes can
cause motor neuron pathology and
death, respiratory and forelimb motor
dysfunction.
mSOD1 in astrocytes can be
recognized as a potential
therapeutic target for ALS;
transplantation of hiPSC-derived
glia-rich progenitors, which then
give rise to astrocytes, into the
cervical or lumbar spinal cord of
ALS patients improves the motor
function.
Lacking standard protocols for
differentiation of hiPSCs to glial
precursors; allowing the
long-term survival; reducing the
immune responses; mitigating
the risk of tumor formation as
well as establishing appropriate
circuitry with host CNS. Several
factors may account for the
cell transplantation effects for
ALS, including patient selection
(disease stages), injection sites
(cervical or lumbar or both),
and modification of cellular
grafts (glial-restricted
precursors with/without GLT1
overexpression).
Haidet-Phillips et al.,
2011
Papadeas et al.,
2011
Kondo et al., 2014
Lepore et al., 2008
Philips and
Robberecht, 2011
Zhu et al., 2002
Boillée et al., 2006
Henkel et al., 2009
Tang and Le, 2016
Microglia Microglia are activated where motor
neuron loss takes place, contributing
to the death of motor neurons;
Minocycline treatment delays ALS
progression through inhibiting
microglial activation; selective removal
of mSOD1 from microglia slows down
disease progression; mSOD1 may
induce M2-microglia to transform into
M1-microglia as disease progresses.
Antibiotics may serve as a
potential therapy for ALS;
mSOD1 in microglia can be
recognized as a potential
therapeutic target for ALS;
Manipulating the balance
between M1 and M2 microglial
phenotypes during specific
stage(s) in ALS may provide
clinical therapeutic benefits.
Spinal cord
injury (SCI)
Astrocytes Transplantation of astrocytes from
murine glial-restricted progenitors
significantly improves behavioral
recovery and induces robust axonal
growth after acute injury of rat spinal
cord; transplantation of
GLT-overexpressing
hiPSCs-astrocytes into rodent
animals reduces lesion size and
promotes preservation of respiratory
functions.
Strategies of transplanting
astrocytes from hiPSCs-derived
glial-restricted progenitors
provide a potential for promoting
regenerative growth of both
motor and sensory axons after
SCI.
Many key factors should be
taken into consideration that
include SCI injury models
(acute, sub-acute and chronic),
source of transplanted cells,
methodologies of assessing
the efficacy of transplanted
cells and the timeframe of
observation after
transplantation.
Davies et al., 2006
Li et al., 2015
Nutt et al., 2013
Hayashi et al., 2011
Oligodendrocytes
(OLs)
Severe loss of OLs leads to
demyelination, and subsequently
activation of OPC proliferation, which
would last for about 1 week.
However, ER stress and negative
regulators (BMP-4, semaphorin 3
etc.) at the injury sites inhibit the
rescue effects of OPCs.
Screening drugs that are
neuroprotective and/or able to
promote maturation and
remyelination of OPCs in the
lesioned cord; testing the optimal
cell dosage and time points after
SCI; combining cellular grafts
with drug treatment for SCI, such
as clemastine and benzaltolide
etc.
Optimal implantation time
window; accurate animal
models; limitation of
transplanting a single type of
cells; survival, maturation, and
remyelination of donor OPCs in
host cord.
Zai and Wrathall,
2005; Lytle et al.,
2009; Xiao et al.,
2010; Jang et al.,
2011; Mei et al.,
2014; Imai et al.,
2018
Alzheimer’s
disease (AD)
Microglia Microglia recruitment serves as part
of the attempt of the CNS to clear Aβ
deposition, which plays a
neuroprotective role at the early stage
of AD; but as disease progresses,
microglia become dysfunctional and
pro-inflammatory cytokines released
by microglia downregulate genes
involved in Aβ clearance pathways,
therefore contributing to Aβ
accumulation and neurodegeneration
at the late stage of AD.
Inflammatory processes,
including activated microglia
accumulation, have been
demonstrated to contribute to
neuronal damage in AD,
suggesting anti-inflammatory
strategies may offer some
neuroprotection.
A previous clinical trial reported
negative results from
prednisone treatment in AD
patients. But the
anti-inflammatory strategy for
AD treatment should not be
nullified. Additional endpoints,
more anti-inflammatory drugs
of various doses, and other
inflammation biomarkers
should be tested in future trials.
El Khoury et al., 2007
Hickman et al., 2008
Liu et al., 2010
Tang and Le, 2016
Koch and Szecsey,
2000
(Continued)
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TABLE 2 | Continued
Diseases
involving glia
Cell types Representative roles in disease
pathology
Potential applications Challenges References
Multiple
Sclerosis (MS)
OLs OPCs could restore part of the myelin
damage during the remission phase;
but in the progressive phase,
endogenous OPCs fail to rescue the
demyelinated axons, which ultimately
leads to neurological function deficits.
Transplanted hiPSC-OPCs into
EAE models at different phases of
disease to evaluate the differences
in therapeutic effect; combining
cell transplantation with drug
treatment for treatment of MS,
such as clemastine, benzaltolide
and/or rHIgM22 etc.
Survival, maturation and
remyelination of donor OPCs in
host cord; insufficiency of animal
models to reflect human
diseases.
Bjartmar and Trapp,
2001
Pirko et al., 2004
Kuhlmann et al., 2008
Tallantyre et al., 2010
Boyd et al., 2013
Mei et al., 2014
Thiruvalluvan et al.,
2016
the late disease phase, indicating that mSOD1 in microglia can
be recognized as a potential therapeutic target for ALS (Boillée
et al., 2006). Interestingly, M1 and M2 microglial phenotypes
may switch during ALS disease development. Intracellular
and extracellular misfolded mutant SOD1 may play critical
roles in regulating the transformation from anti-inflammatory
M2 phenotype to pro-inflammatory M1 phenotype as disease
progresses, through promoting the generation and release of
reactive oxygen species and exaggerating pro-inflammatory
signaling in microglia (Henkel et al., 2009; Tang and Le, 2016).
Collectively, while the M2-like microglia appear to be protective
in the first response, the following sustained neuro-inflammatory
cytokine cascade and neuronal stress exerted by mutant SOD1
induce microglia to transform into M1-like phenotype. From
a therapeutic perspective, manipulating the balance between
M1 and M2 microglial phenotypes during specific stage(s)
in neurodegenerative diseases may provide clinical therapeutic
benefits. In conclusion, the cellular pathogenesis of ALS is not
limited to motor neuron abnormalities but extend to glial cells,
such as astrocytes and microglia. These studies suggest that
transplantation of hiPSCs-derived glial precursor cells, which are
promising candidates for cell replacement therapy due to their
efficient glial restricted differentiation, low risk of tumorigenesis,
and good survival capacity, may improve the microenvironment
around motor neurons in ALS. However, there is still a long
way to go before we can have a complete picture of how
microglia and astrocytes contribute to ALS, and how we can
efficiently employ hiPSCs-derived microglia and astrocytes for
treatment of ALS as a cell-based therapy. Challenges include:
a lack of standard protocols for differentiation of hiPSCs to
glial precursors; immune responses caused by allogeneic glial
grafts; how to eliminate the risk of tumor formation; and
how to establish appropriate (and avoid inappropriate) circuitry
with host cells. Furthermore, several factors may account for
the cell transplantation efficacy for ALS, including selection of
patients (genetic background affects efficacy?), time window of
intervention (early or late stage?), injection sites (cervical or
lumbar or both?), etc.
Spinal Cord Injury
SCI is a devastating condition in which injury to spinal cord
leads to extensive neural damage and severe motor or sensory
functional deficits (Holmes, 2017). A large body of literature has
focused on hiPSC-based transplantation strategies for promoting
regenerative growth of both motor and sensory axons after SCI
(Nori et al., 2011; Fujimoto et al., 2012). Transplantation of
astrocytes from murine glial-restricted progenitors significantly
improves behavioral recovery and induces robust axonal growth
after acute injury of rat spinal cord (Davies et al., 2006).
A cascade of downstream mechanisms termed “secondary
injury” follows the initial injury-mediated axotomy of passing
axons and cell death in SCI, including glutamate excitotoxicity
caused by dysfunction of extracellular glutamate homeostasis
(Park et al., 2004). Therefore, Li et al. engineered hiPSC-
derived astrocytes with lentiviral vectors encoding GLT1 and
transplanted these cells into rodent animals (Li et al., 2015).
GLT1-overexpressing hiPSCs-astrocytes reduce lesion size and
promote preservation of diaphragmatic respiratory functions of
SCImodel animals compared with unmodified hiPSCs-astrocytes
and human fibroblast control group (Li et al., 2015). Nevertheless,
Nutt et al. examined the potential of caudalized hiPSC-derived
NPCs to repair early chronically (4 weeks post-injury) injured
spinal cord (Nutt et al., 2013), and found that caudalized hiPSC-
derived NPCs develop into neurons and glia which survive for
up to 2 months but without significant restoration of forelimb
functions (Nutt et al., 2013). Moreover, Hayashi et al. utilized
mouse iPSCs to differentiate to astrocytes and transplanted then
into rats 3 or 7 days after spinal injury (Hayashi et al., 2011).
The results revealed that the animal groups injected with iPSC-
derived astrocytes do not show remarkable improvement and
even display greater sensitivity to mechanical stimulus than
control group treated with Dulbecco’s Modified Eagle Medium
(Hayashi et al., 2011). These findings suggest that many key
factors should be taken into consideration that include SCI injury
models (acute, sub-acute, and chronic), source of transplanted
cells, methodologies of assessing the efficacy of transplanted
cells and the timeframe of observation after transplantation. For
example, it is possible that recovery may take longer time in the
chronic injury model than in the acute or sub-acute phase, and
it is also reasonable that endogenous repair mechanisms have
less influence in the chronic injury setting than in the acute or
sub-acute model.
SCI could also cause severe loss of OLs, leading to
demyelination. As a result, OPCs would be activated and respond
rapidly to SCI (Crawford et al., 2014). The rate of OPC
proliferation remarkably increases by day 1 after SCI and last for
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about 1 week, then decrease gradually (Zai and Wrathall, 2005;
Lytle et al., 2009). However, the hostile microenvironment of
the injury sites plays a detrimental role to their rescue effects,
for instance, the existence of negative regulators that include
chondroitin sulfate proteoglycans, semaphorin 3, leucine-rich
repeat and Ig domain-containing 1, BMP-4 etc. (Fawcett and
Asher, 1999; Ji et al., 2006; Xiao et al., 2010), and the formation
of glial scars and cavity caused by astrogliosis (Jang et al., 2011).
In the meantime, endoplasmic reticulum (ER) stress could also
lead to apoptosis of OPCs (Imai et al., 2018). To date, therapeutic
strategies to treat SCI have shown limited efficacy in clinics,
and even spinal decompression can be only applied to select
cases (Furlan et al., 2016; Goldman, 2018). Due to the lack of
effective therapies for spinal cord injuries, transplantation of
hiPSC-derived OPCs becomes a potential treatment. In 2015,
All et al. transplanted hiPSC-derived OPCs into a moderate
contusive SCI model in rats 24 h after injury (All et al., 2015). In
this study, all rats were treated with cyclosporine A daily 3 days
before cell transplantation until the end of the experiment (All
et al., 2015). After 2 months, compared with the control group,
the OPCs-treated group revealed the survival and differentiation
of hiPSC-derived OPCs, less cavitation, more remyelination of
axons, and improvement of motor behaviors (All et al., 2015).
Importantly, no tumor formation was detected (All et al., 2015).
This study suggests that transplantation of cells 24 h after SCI can
reduce astrogliosis and inflammation (All et al., 2015). A different
time point of transplantation was tested by Kawabata et al. In
this study, the authors injected hiPSCs-OPCs enriched neural
stem/progenitor cells (hiPSCs-OPC-enriched NS/PCs) into the
lesion epicenter of T10 level in NOD-SCID mice on the 9th
day after injury (Kawabata et al., 2016). Twelve weeks later, the
grafted cells migrated out of the lesion site and differentiated into
mature OLs, astrocytes and neurons, and these cells contributed
to remyelination, functional recovery, and synapse formation
between host neurons and grafted cells (Kawabata et al., 2016).
In their previous studies, hiPSCs-neural stem/progenitor cells
were transplanted but with an inefficient generation of OLs
in vivo; accordingly, there was no significant improvement of
motor functions after transplantation (Nori et al., 2011, 2015). To
evaluate the effects of iPSCs-based therapy in immunocompetent
animals, Pomeshchik et al. used tacrolimus-immunosuppressed
C57BL/6J mice to test the effects of hiPSC-derived NPCs in
SCI (Pomeshchik et al., 2015). However, the results showed
that the transplanted cells did not lead to functional recovery
(Pomeshchik et al., 2015).
In light of the limitations of rodent animals in modeling
human diseases, large animal models are needed for safety
and efficacy examinations prior to any possible clinical trials
in human. Kobayashi et al. conducted the transplantation
experiments in a non-human primate SCI model (Kobayashi
et al., 2012). Twelve weeks after engraftment of hiPSCs-neural
stem/progenitor cells into the fifth cervical level (C5) of spinal
cord, the grafted cells show positive effects in both tissue
histology and functional recovery (Kobayashi et al., 2012). In
another recent study, Tuszynski and colleagues grafted human
spinal cord–derived NPCs into nine adult male rhesus monkeys,
which had received right-side hemisection lesions at C7 segment
(Rosenzweig et al., 2018). Five successfully grafted subjects
showed that human NPCs survived in the lesion sites for at
least 9 months without development of teratoma or tumor; OLs
and mature astrocytes were detected 5 months post-grafting,
and large numbers of axons developed from grafts into distant
areas of host spinal cord. Meanwhile, improvements of forelimb
functions were detected in the primate models (Rosenzweig et al.,
2018). Besides, the authors identified critical steps to achieve
successful grafting into large lesion cavities, which included
draining the CSF at the lesion site and applying fibrin–thrombin
in the grafting mixture (Rosenzweig et al., 2018).
Caution needs to be taken when interpreting the results. In
most of the xeno-transplantation studies using hiPSC derivatives
or human fetal tissues/cells as donor cells, immunosuppressant
drugs were administered. The observed positive effects, such as
reduced inflammation, inhibited scar tissue formation, decreased
gliogenesis, undetectable tumor formation, etc. may also result
from effects of immunosuppression per se. Clinical trials are
needed to address these issues. Since 2015, a phase I/II clinical
trial has been initiated, which was aimed to evaluate the safety
of dose escalation of AST-OPC1 in SCI patients (NCT02302157).
AST-OPC1, an early-stage OPC population differentiated from
hESCs, were used as donor cells. The safety and efficacy of AST-
OPC1 had been tested in rodent SCI models, and the biological
activities, biodistribution, toxicology, and tumorigenicity of the
grafts had been assessed (Priest et al., 2015).
Transplantation of OPCs for SCI treatment has been
contemplated since long ago; however, many challenges still
exist in the field. For example, how to increase the survival
of grafts; how to promote maturation and myelination of
donor OPCs in host cord; what is the optimal implantation
time window after SCI, etc. To enhance the efficacy of OPC
transplantation, Imai et al. demonstrated that treatment with
amiloride promotes OPC survival and remyelination after SCI
in rats (Imai et al., 2018). Eight FDA-approved antimuscarinic
compounds such as clemastine and benzaltolide could also
enhance OL differentiation and remyelination (Mei et al., 2014).
Based on their findings, a combinatory approach applying small
molecules together with cellular grafts may be a promising
strategy, which warrants further effort. In addition, SCI is often
associated with large cavity in the lesioned areas; implanting
OPC cellular graft alone may not be sufficient to re-bridge
the sectioned connection. Adding synapse-forming neuronal
precursors as a relay, with myelin-forming OPCs, may possibly
achieve a better therapeutic result.
Alzheimer’s Disease
As the most common cause of dementia, AD is a
neurodegenerative disorder characterized by increasing memory
loss, personality changes and finally cognitive impairment
(Bateman et al., 2012). The accumulation of amyloid β (Aβ), and
tau hyperphosphorylation, two pathological hallmarks of AD,
lead to synaptic and neuronal loss as well as neuroinflammation
(Bateman et al., 2012; Jack et al., 2013). Aβ aggregates can attract
and induce activation of primary microglia. As the resident
immune cells of the CNS, microglia have been demonstrated to
be able to phagocytose amyloid fibrils; and microglia dysfunction
could accelerate Aβ aggregates, leading to neurodegeneration
and progression of AD (El Khoury et al., 2007; Johansson et al.,
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2015). Emerging evidence shows that microglia play a protective
role in AD progression via clearing Aβ deposition. However, the
roles of microglia in AD may be a double-edged sword, which
should be taken into account when contemplating microglial or
anti-inflammatory therapy for AD (Hickman et al., 2008; Tang
and Le, 2016). On the one hand, microglia recruitment serves
as part of the attempt of the CNS to clear Aβ deposition, which
plays a neuroprotective role at the early stage of AD (El Khoury
et al., 2007; Hickman et al., 2008; Liu et al., 2010). On the other
hand, as disease progresses, microglia become dysfunctional and
pro-inflammatory cytokines released by microglia downregulate
genes involved in Aβ clearance pathways, including Aβ-binding
receptors and Aβ-degrading enzymes, therefore contributing
to Aβ accumulation and neurodegeneration at the late stage
of AD (El Khoury et al., 2007; Hickman et al., 2008). Abud
et al. transplanted hiPSC-derived microglia-like cells (day 38
of differentiation) into the cortex of mice, and found that
these microglia-like cells survived, displayed highly branched
morphology and expressed markers such as IBA1, TMEM119,
and P2RY12 (Abud et al., 2017). Moreover, microglia-like cells
derived from hiPSCs were transplanted into the hippocampi
of AD mice to examine their roles in AD pathology (Abud
et al., 2017). hiPSC-derived microglia-like cells migrated
toward Aβ deposition and phagocytosed fibrillar Aβ as well
as tau protein (Abud et al., 2017), providing a platform where
hiPSC-derived microglia-like cells can be used to investigate
microglial functions in AD pathology and therapy. Furthermore,
genome-wide association studies have revealed that several
genes expressed by microglia are involved in the regulation
of neuro-inflammation in AD progression, such as CD33 and
TREM2 (Villegas-Llerena et al., 2016). And inflammatory
processes, including accumulation of activated microglia,
have been demonstrated to contribute to neuronal damage
in AD, suggesting that anti-inflammatory intervention may
offer some neuroprotection (Tang and Le, 2016). A great
number of laboratory and epidemiologic studies support that
anti-inflammatory drugs decrease the incidence of AD to
some extent (McGeer et al., 1996). However, a randomized,
placebo-controlled multicenter trial indicates that low dose
prednisone used in the study was ineffective in slowing the rate
of cognitive decline in AD patients (Koch and Szecsey, 2000).
There was no significant difference in cognitive decline between
the prednisone and placebo treatment groups, as measured by
the 1-year change in AD Assessment Scale (Koch and Szecsey,
2000). Despite the negative results reported in this clinical trial,
the anti-inflammatory strategy for AD treatment should not
be nullified. The primary end points used in the study might
not accurately reflect the contribution of brain inflammation
in cognitive decline in AD. The correlation of inflammation
and cognitive functions could be examined by testing more
biomarkers of inflammation. Also, not seeing the effect of one
particular drug prednisone does not nullify the possibility that
other drugs may work. In short, hiPSC-derived microglia-
like cells can be utilized to interrogate genotype-phenotype
relationships in AD, and allow for studying human microglial
functions in AD pathology and therapy.
MS
MS is the most common chronic neurological disorder
among children and young adults, which is characterized
by inflammation, demyelination, progressive axonal loss, and
retrograde neuronal degeneration (Bjartmar and Trapp, 2001;
Tallantyre et al., 2010). The disease eventually leads to motor
function defects and cognitive impairments. However, the
pathogenesis of MS is still unclear. Autoimmune responses, and
genetic and environmental factors are believed to be involved in
MS (Ascherio and Munger, 2007a,b; Oksenberg and Baranzini,
2010; Hauser et al., 2013). In terms of treatment, the major
strategy is anti-inflammatory and immunosuppressive regimens.
However, these therapies not only cause a range of side effects but
also fail to stop the continuously progressing pathology of MS.
Therefore, how to achieve neuroprotection and remyelination
becomes the key for MS therapy. In the demyelinated lesions,
there seems to exist premyelinating OPCs, astrocytes, microglia,
and NPCs (Lucchinetti et al., 2000; Chang et al., 2002; Nicaise
et al., 2017). During the remission phase of MS, OPCs can
repair the myelin damage to some extent; however, in the
progressive phase, endogenous OPCs fail to sufficiently rescue
the demyelinated axons (Kuhlmann et al., 2008; Boyd et al., 2013;
Thiruvalluvan et al., 2016). Given the remyelination defect of
endogenous OPCs in MS, hiPSC-derived OPCs hold promise as
donor cells in cell replacement therapies.
hiPSC-derived OPCs can differentiate into OLs and
remyelinate damaged axons in MS models (Wang et al., 2013;
Douvaras et al., 2014; Thiruvalluvan et al., 2016). Most earlier
studies used shiverer mice or cuprizone-induced demyelination
mice as MS models. However, there are significant differences
between these models and MS patients in terms of clinical and
pathological presentations. The later established experimental
autoimmune encephalomyelitis (EAE) models appear better for
MS modeling. Particularly, non-human primate EAE models
so far remain the most closely resembling model for studying
the pathogenesis and treatment of MS (Jagessar et al., 2010).
Thiruvalluvan et al. reported, for the first time, transplantation
of hiPSC-derived OPCs into marmoset EAE models. After the
authors examined the proper functionalities of hiPSCs-OPCs
in vitro and in mice, the cells were injected into the cerebral
cortex of marmoset (Thiruvalluvan et al., 2016). At different time
points following engraftment, hiPSCs-OPCs show a capacity
of survival, migration and remyelination (Thiruvalluvan et al.,
2016). This study provided an important theoretical basis for cell
replacement therapy of MS.
Some of the clinical trials for MS treatment were aimed to
test the safety and/or efficacy of vitamins, antibodies, and growth
factors [Vitamin A, NCT01407211, NCT01225289; Vitamin
D, NCT01952483; recombinant human monoclonal antibody
22 (rHIgM22), NCT01803867, NCT02398461; recombinant
human insulin-like growth factor (rhIGF-1), NCT00001669].
HIgM22 exists in MS patients’ serum, which could promote
remyelination (Pirko et al., 2004). Another phase I clinical trial
has been initiated to culture OPCs from human patients, with
a long-term goal of therapeutic application of these cultured
cells for treatment of demyelinating diseases (NCT00283023).
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Interventional strategies for MS need to consider both the
microenvironment of the demyelination sites and the selection
of cellular grafts. It may not be surprising that a combinatory
approach targeting both the niche of lesioned brain and
application of OPCs for replacement is tested in future trials.
Small molecules and biomaterial scaffold that could promote the
survival, differentiation, and/or function of engrafted OPCs, may
also be incorporated into the interventional strategy for a better
effect.
SUMMARY AND FUTURE PERSPECTIVE
It is increasingly clear that glial cells not only have a passive
and supporting role but also make other critical contributions
in the CNS—they are indispensable for brain homeostasis,
development, and functions, and also participate in a variety of
neurological diseases. However, the research on glial cells has
been hampered by a constellation of challenges that include
difficulties in culturing them in vitro, limited accessibility of
human neural tissues, altered characteristics by the isolation
procedure, and insufficiency of rodent animals in modeling
human diseases involving glial cells due to the large distinctions
in morphology, function, and cell type distribution in humans
vs. rodents. New advances in the field of hiPSC technology
allow for generation of glial cells by differentiating hiPSCs
into various glial cells in defined media, providing a potential
platform to better understand the role of glial cells in
CNS development and function. hiPSC-derived glial cells can
be employed to model some complex neurological diseases,
such as ALS, SCI, AD, MS, facilitating the understanding
of glia-related mechanisms underlying disease etiology and
development.
A few clinical trials have been initiated in which glial cells
derived from fetal tissues or hiPSCs would be applied to
treat certain neurological diseases, such as ALS, SCI, and AD.
Engraftment of glial cells is aimed at either replacing the damaged
glia or nourishing the microenvironment of degenerating cells.
Despite the robust potential of iPSC derivatives in disease
modeling and treatment, caution needs to be taken when moving
to the clinical application stage. A number of issues should be
taken into account as follows. (i) Caveats of iPSC reprogramming
technology. Mutation accumulation is inevitable during the
reprogramming process and the subsequent expansion of iPSC
clones. Careful examination is necessary to identify any harmful
mutations associated with cancer development or functions of
the target cells. With regard to the familial disease patients,
the reprogramming technology may need to be combined with
gene editing technology for correction of the mutant genes.
Yet whole genome deep sequencing would be required to
investigate any possible off-target effects. Compared to off-shelf
drugs, individualized strategy using iPSC derivatives is costly
and requires lengthy preparation and validation of donor cell
quality and efficacy, which would further limit the number
of eligible patients and applicable diseases/indications. The
tumorigenic risk has always been a concern associated with
application of iPSC derivatives. Any remaining undifferentiated
pluripotent cell would pose serious risk after transplantation.
A robust differentiation protocol and rigorous sorting step
may provide a solution. An alternative cell source is induced
neural stem cells, which could give rise to glial cells yet
requires a shorter period of time for the differentiation step.
In addition, the adult stem cell nature of induced neural stem
cells implicates less tumorigenic risk. Furthermore, due to the
rapid advancement of field, regulatory bodies need to come up
with more practical and timely policies to guide the application
of iPSCs and derivatives. Related policies have been lacking
or outdated in some countries. (ii) Patient selection. Each
patient is unique and the disease condition would normally
be much more complex than the condition formulated in an
animal model, in which the number of variables is intentionally
minimized. Current knowledge is still insufficient to determine
the response of individual patient to certain cellular therapy.
A better understanding of the influence of genetic, epigenetic,
and environmental components on the treatment effect would
be essential to identify a responder patient group and the best
disease stage for intervention. To achieve this, it is necessary
to optimize each step involved in the cellular therapy, such as
standardization of cell differentiation, sorting, characterization,
and the dosage and route of cell delivery. (iii) Graft tracing.
Knowing where the cells go and what cells they become would
be critical for evaluation and improvement of the therapy.
However, clinical grade tracing technologies are still very limited.
Nanoparticle labeling may be used for glia graft tracing through
imaging; but there is still a large room for improvement in this
field.
To summarize, along with the rapid progress of stem cell
biology and cell replacement therapy in the past years, we
may witness, hopefully in the foreseeable future, the application
of hiPSC-derived glial cells in the clinic for treatment of
neurological diseases. Nevertheless, some crucial issues need
to be addressed to improve the safety and efficacy of such
therapeutic strategies.
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